FUNDAMENTALS |
MarketCap: |
103 895 mill
|
EPS: |
34.81
|
P/E: |
27.65
|
Earnings Date: |
May 01, 2024 |
SharesOutstanding: |
107.94 mill
|
Avg Daily Volume: |
0.503 mill
|
RATING
2024-03-28 |
S-
|
Strong Buy
|
RATINGS |
Rating CashFlow: |
Strong Buy
|
|
Return On Equity: |
Buy
|
|
Return On Asset: |
Strong Buy
|
|
DE: |
Neutral
|
|
P/E: |
Strong Buy
|
|
Price To Book: |
Strong Buy
|
|
QUARTER GROWTHS |
|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE 27.65 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
4.70x
|
Company: PE 27.65 | industry: PE 5.88
|
DISCOUNTED CASH FLOW VALUE |
$2 409.05
(150.29%)
$1 446.56
|
Date: 2024-03-28
|
Expected Trading Range (DAY) |
$ 944.71 - 980.27
( +/- 1.85%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-03-13 | Murphy Andrew J | Buy | 20 000 | Common Stock |
2024-03-13 | Murphy Andrew J | Sell | 14 217 | Common Stock |
2024-03-14 | Murphy Andrew J | Sell | 182 | Common Stock |
2024-03-14 | Murphy Andrew J | Sell | 444 | Common Stock |
2024-03-14 | Murphy Andrew J | Sell | 576 | Common Stock |
INSIDER POWER |
-30.83
|
Last
100 transactions |
Buy:
231 452 | Sell:
437 703 |
Forecast:
16:00 - $962.48
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $962.48
Forecast 2: 16:00 - $962.48
Forecast 3: 16:00 - $962.48
SCORE
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$962.49 (-0.39% )
|
Volume |
0.447 mill
|
Avg. Vol. |
0.503 mill
|
% of Avg. Vol |
88.74 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For REGN
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date |
Signal |
@ |
Closed |
% |
Feb 8 - 15:34 | sell | $944.13 | N/A | Active |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.